[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345844-105":59,"doc-detail-345844-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","next-generation-sequencing-based-characterization-of-brca12-variants-across-multiple-tumor-types-in-vietnamese-patients","Next-generation sequencing-based characterization of BRCA1/2 variants across multiple tumor types in Vietnamese patients","","Mutations in BRCA1 and BRCA2 genes are central to the development of multiple cancers, and identifying them is essential for selecting patients for targeted treatment. In Vietnam, large-scale data on BRCA1/2 mutation frequency and clinical utility remain limited. This study reports the prevalence of BRCA1/2 mutations across several cancer types, assesses next-generation sequencing (NGS) for copy-number variant detection, and evaluates the clinical relevance of the results in Vietnamese patients.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/next-generation-sequencing-based-characterization-of-brca12-variants-across-multiple-tumor-types-in-vietnamese-patients/345844/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/next-generation-sequencing-based-characterization-of-brca12-variants-across-multiple-tumor-types-in-vietnamese-patients/345844.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of this study?","Question",{"text":112,"@type":113},"To report the prevalence of BRCA1/2 mutations across different cancer types in Vietnamese patients, evaluate NGS for copy-number variant detection, and interpret the clinical significance of the findings.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were BRCA1/2 variants and copy-number variants detected?",{"text":117,"@type":113},"BRCA1/2 mutations were tested using the AmoyDx BRCA-PRO KIT and Illumina NextSeq 550 NGS platform, and copy-number variants were detected from blood-derived DNA and confirmed by MLPA.",{"name":119,"@type":110,"acceptedAnswer":120},"What cancers showed the highest rate of pathogenic BRCA1/2 variants?",{"text":121,"@type":113},"Among 1,101 unselected patients, pathogenic variants were found in 158 cases (14.35%), with the highest mutation burden in ovarian cancer and triple-negative breast cancer (TNBC).",{"name":123,"@type":110,"acceptedAnswer":124},"What clinical relevance do the authors emphasize?",{"text":125,"@type":113},"The results suggest a substantial subset of tumors with homologous recombination deficiency, indicating potential sensitivity to PARP inhibitors and platinum-based chemotherapy, and they support the utility of NGS-based BRCA1/2 genotyping for therapeutic and hereditary risk decisions.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},345844,1790342747,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":36,"preview_page_count":19,"preview_urls":149},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Nguyen et al. BMC Cancer (2026) 26:858 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16085-0](https://doi.org/10.1186/s12885-026-16085-0)  \nRESEARCH Open Access  \nNext-generation sequencing-based characterization of BRCA1/2 variants across multiple tumor types in Vietnamese patients  \nHong-Thanh Nguyen1,2, Minh-Duc Vu1,2, Dinh-Dung Nguyen1,2, Phuong-Nhung Dinh1, Van-Quy Hoang1, Linh-Trang Ngoc Bui1, Dinh-Tuan Nguyen1, Phuoc-Huy Do3, Thi-Oanh Tong1, Van-Hung Nguyen 1, Thu-Huong Thi Han1, Sy-Tung Ha1, Huy-Duong Do1, Thanh-HaThi Ly1 and Viet-Nhan Nguyen 1*  \nAbstract  \nBackground Mutations in the BRCA1 and BRCA2 genes play a pivotal role in the pathogenesis of breast, ovarian, prostate, pancreatic, and several other cancers. Identification of these mutations is crucial for selecting patients eligible for targeted therapy. In Vietnam, large-scale data on BRCA1/2 mutation prevalence and clinical utility are limited. We aim to report the prevalence of BRCA1/2 mutations across different cancer types, evaluate the effectiveness of next-generation sequencing (NGS) in copy-number variant detection, and discuss the clinical significance of the findings.  \nMethods A total of 1,101 Vietnamese patients diagnosed with breast, ovarian, prostate, or pancreatic cancer underwent BRCA1/2 mutation test atVinmec. The test utilized the AmoyDx BRCA-PRO KIT and the Illumina NextSeq 550 NGS platform. Copy-number variants were detected by NGS solely in blood-derived DNA samples and were systematically confirmed by MLPA.  \nResults Among 1,101 unselected patients with breast, ovarian, prostate, or pancreatic cancer, pathogenic BRCA1/2 variants were identified in 158 (14 . 35%), including 57/158 of ovarian, 78/158 triple-negative, 16/158 of prostate, 4/158 of pancreatic and 3/158 HR-positive breast cancer. The mutation burden was highest in ovarian cancer and TNBC, where BRCA1 variants predominated over BRCA2 (40/57 BRCA1 vs 17/57 BRCA2 in ovarian cancer and 57/78 BRCA1 vs 21/78 BRCA2 inTNBC) . Several BRCA1 truncating variants (c.4997dup, c. 5251C >T, c. 5335del) and recurrent BRCA2 loss-of-function variants were enriched in triple-negative breast cancer (TNBC), with additional cases observed in ovarian, prostate, and pancreatic cancers. Notably, two heterozygous copy-number losses were observed in our series:  \nBRCA1 exon 2 deletion (three TNBC and one ovarian cancer) and BRCA2 exon 22–23 deletion (one TNBC and one prostate cancer) .  \nConclusions This study provides one of the first large next-generation sequencing—based BRCA1/2 datasets in Vietnam, indicating a sizable subset of tumors with homologous recombination deficiency and potential sensitivity to PARP inhibitors and platinum-based chemotherapy. These findings underscore the clinical utility of NGS-based  \n*Correspondence:  \nViet-Nhan Nguyen [v.nhannv2@vinmec.com](v.nhannv2@vinmec.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc","cbCaic5nYP3ukds7","https://ap.wps.com/l/cbCaic5nYP3ukds7","pdf",3365030,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords","[{\"question\":\"What is the main purpose of this study?\",\"answer\":\"To report the prevalence of BRCA1/2 mutations across different cancer types in Vietnamese patients, evaluate NGS for copy-number variant detection, and interpret the clinical significance of the findings.\"},{\"question\":\"How were BRCA1/2 variants and copy-number variants detected?\",\"answer\":\"BRCA1/2 mutations were tested using the AmoyDx BRCA-PRO KIT and Illumina NextSeq 550 NGS platform, and copy-number variants were detected from blood-derived DNA and confirmed by MLPA.\"},{\"question\":\"What cancers showed the highest rate of pathogenic BRCA1/2 variants?\",\"answer\":\"Among 1,101 unselected patients, pathogenic variants were found in 158 cases (14.35%), with the highest mutation burden in ovarian cancer and triple-negative breast cancer (TNBC).\"},{\"question\":\"What clinical relevance do the authors emphasize?\",\"answer\":\"The results suggest a substantial subset of tumors with homologous recombination deficiency, indicating potential sensitivity to PARP inhibitors and platinum-based chemotherapy, and they support the utility of NGS-based BRCA1/2 genotyping for therapeutic and hereditary risk decisions.\"}]","Next-generation sequencing-based characterization of BRCA1/2 variants across multiple tumor types in Vietnamese patients | PDF",1790059082,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a280e27eb4007cf4bba988bbf4e3bb71.webp",983,1310,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd6267217ea961848f64c1d9522ed296.webp",982,1309,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/325346c06a8c8851ea77140132389f16.webp",981,1308,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c228267a5fd342d04f780bbb164fc68c.webp",980,1306]